Patents by Inventor Wolfgang Mundt

Wolfgang Mundt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant cell clones having increased stability and methods of making and using the same
    Patent number: 7094574
    Abstract: Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.
    Type: Grant
    Filed: May 6, 2005
    Date of Patent: August 22, 2006
    Assignee: Baxter Aktiengesellschaft
    Inventors: Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
  • Animal protein-free media for cultivation of cells
    Publication number: 20060094104
    Abstract: The present invention relates to animal protein-free cell culture media comprising polyamines and a plant and/or yeast-derived hydrolysate. The invention also relates to animal protein-free culturing processes, wherein cells can be cultivated, propagated and passaged without adding supplementary animal proteins in the culture medium. These processes are useful in cultivating cells, such as recombinant cells or cells infected with a virus, and for producing biological products by cell culture processes.
    Type: Application
    Filed: October 29, 2004
    Publication date: May 4, 2006
    Inventors: Leopold Grillberger, Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
  • Method for large scale production of virus antigen
    Patent number: 6951752
    Abstract: The present invention provides improved methods of production of viral antigen on a culture of adherent cells bound to a microcarrier, wherein the methods provide for increased viral antigen yield per culture medium volume. The invention is also directed to a cell culture biomass of adherent cells having increased cell density and microcarrier concentration compared to the respective confluent cell culture.
    Type: Grant
    Filed: December 10, 2001
    Date of Patent: October 4, 2005
    Assignee: Bexter Healthcare S.A.
    Inventors: Manfred Reiter, Wolfgang Mundt
  • Recombinant cell clones having increased stability and methods of making and using the same
    Publication number: 20050196843
    Abstract: Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.
    Type: Application
    Filed: May 6, 2005
    Publication date: September 8, 2005
    Applicants: Baxter Aktiengesellschaft, Baxter Healthcare Corporation
    Inventors: Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
  • Recombinant cell clones having increased stability and methods of making and using the same
    Patent number: 6936441
    Abstract: Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.
    Type: Grant
    Filed: June 12, 2002
    Date of Patent: August 30, 2005
    Assignee: Baxter Aktiengesellschaft
    Inventors: Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
  • Large scale productions of virus antigen
    Publication number: 20050181495
    Abstract: The present invention provides improved methods of production of viral antigen on a culture of adherent cells bound to a microcarrier, wherein the methods provide for increased viral antigen yield per culture medium volume. The invention is also directed to a cell culture biomass of adherent cells having increased cell density and microcarrier concentration compared to the respective confluent cell culture.
    Type: Application
    Filed: March 17, 2005
    Publication date: August 18, 2005
    Applicant: Baxter Healthcare S.A.
    Inventors: Manfred Reiter, Wolfgang Mundt
  • Method of isolation and purification of trypsin from pronase protease and use thereof
    Publication number: 20050069534
    Abstract: The present invention provides methods of isolation and purification of Streptomyces griseus trypsin (SGT) from pronase in a single affinity chromatography step and uses of the purified SGT.
    Type: Application
    Filed: September 17, 2004
    Publication date: March 31, 2005
    Applicant: Baxter Healthcare S.A.
    Inventors: Artur Mitterer, Christa Tauer, Manfred Reiter, Wolfgang Mundt
  • Method of large scale production of Hepatitis A virus
    Patent number: 6855535
    Abstract: The present invention provides methods of large scale production of Hepatitis A Virus (HAV) on VERO cells bound to microcarrier. The invention also provides for methods of isolation of HAV from the cell culture supernatant of HAV infected VERO cells.
    Type: Grant
    Filed: December 10, 2001
    Date of Patent: February 15, 2005
    Assignee: Baxter Healthcare S.A.
    Inventors: Heidi Meyer, Manfred Reiter, Wolfgang Mundt, Noel Barrett, Friedrich Dorner
  • Method of isolation and purification of trypsin from pronase protease and use thereof
    Patent number: 6830917
    Abstract: The present invention is directed to methods of isolation and purification of Streptomyces griseus trypsin (SGT) from PRONASE protease in a single affinity chromatography step and uses of the purified SGT.
    Type: Grant
    Filed: December 10, 2001
    Date of Patent: December 14, 2004
    Assignee: Baxter Healthcare S.A.
    Inventors: Artur Mitterer, Christa Tauer, Manfred Reiter, Wolfgang Mundt
  • Animal protein free media for cultivation of cells
    Publication number: 20040077086
    Abstract: The present invention relates to animal protein free cell culture media comprising a combination of non-animal derived peptides derived from soy hydrolysate and yeast hydrolysate. The invention also provides an animal protein free culture process, wherein cells are cultivated, propagated and passaged without animal-derived components. This process is useful for cultivating cells, such as recombinant cells or cells infected with a virus, and for production biological products by cell culture processes under conditions devoid of animal protein components.
    Type: Application
    Filed: July 8, 2003
    Publication date: April 22, 2004
    Inventors: Manfred Reiter, Wolfgang Mundt, Leopold Grillberger, Barbara Kraus
  • Medium for the protein-free and serum-free cultivation of cells
    Publication number: 20030203448
    Abstract: A medium is described for the protein-free and serum-free cultivation of cells, especially mammalian cells, whereby the medium contains a proportion of soy hydrolysate.
    Type: Application
    Filed: April 1, 2003
    Publication date: October 30, 2003
    Inventors: Manfred Reiter, Wolfgang Mundt, Friedrich Dorner, Leopold Grillberger, Artur Mitterer
  • Method of isolation and purification of trypsin from pronase and use thereof
    Publication number: 20030124650
    Abstract: The present invention provides methods of isolation and purification of Strepomyces griseus trypsin (SGT) from pronase in a single affinity chromatography step and uses of the purified SGT.
    Type: Application
    Filed: December 10, 2001
    Publication date: July 3, 2003
    Inventors: Artur Mitterer, Christa Tauer, Manfred Reiter, Wolfgang Mundt
  • Method of large scale production of Hepatitis A Virus
    Publication number: 20030108861
    Abstract: The present invention provides methods of large scale production of Hepatitis A Virus (HAV) on VERO cells bound to microcarrier. The invention also provides for methods of isolation of HAV from the cell culture supernatant of HAV infected VERO cells.
    Type: Application
    Filed: December 10, 2001
    Publication date: June 12, 2003
    Inventors: Heidi Meyer, Manfred Reiter, Wolfgang Mundt, Noel Barrett, Friedrich Dorner
  • Method for large scale production of virus antigen
    Publication number: 20030108860
    Abstract: The present invention provides improved methods of production of viral antigen on a culture of adherent cells bound to a microcarrier, wherein the methods provide for increased viral antigen yield per culture medium volume. The invention is also directed to a cell culture biomass of adherent cells having increased cell density and microcarrier concentration compared to the respective confluent cell culture.
    Type: Application
    Filed: December 10, 2001
    Publication date: June 12, 2003
    Inventors: Manfred Reiter, Wolfgang Mundt
  • Enveloped virus vaccine and method for production
    Publication number: 20030108859
    Abstract: The present invention provides methods of production of a purified enveloped virus antigen. In particular, it provides purified Ross River Virus (RRV) antigens, and vaccines comprising purified, inactivated Ross River Virus (RRV) antigen.
    Type: Application
    Filed: December 10, 2001
    Publication date: June 12, 2003
    Inventors: Otfried Kistner, Manfred Reiter, Axel Bruehmann, Noel Barrett, Wolfgang Mundt, Friedrich Dorner
  • Recombinant cell clones having increased stability and methods of making and using the same
    Publication number: 20020182679
    Abstract: Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.
    Type: Application
    Filed: June 12, 2002
    Publication date: December 5, 2002
    Applicant: Baxter Healthcare Corporation
    Inventors: Manfred Reiter, Wolfgang Mundt, Freidrich Dorner
  • Recombinant cell clones having increased stability and methods of making and using the same
    Patent number: 6475725
    Abstract: Disclosed are stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.
    Type: Grant
    Filed: June 2, 1999
    Date of Patent: November 5, 2002
    Assignee: Baxter Aktiengesellschaft
    Inventors: Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
  • Influenza virus vaccine composition
    Patent number: 6372223
    Abstract: This invention describes an influenza virus vaccine containing an influenza virus antigen obtained from a cell culture, with an influenza virus antigen content between 1 &mgr;g and 5 &mgr;g per dose and aluminum as an adjuvant as well as a method for its preparation.
    Type: Grant
    Filed: June 12, 2001
    Date of Patent: April 16, 2002
    Assignee: Baxter Aktiengesellschaft
    Inventors: Otfried Kistner, Noel Barrett, Wolfgang Mundt, Friedrich Dorner
  • Method for isolation of highly pure von willebrand factor
    Patent number: 6103693
    Abstract: The invention relates to a method for isolation of highly pure von Willebrand Factor in which recombinant von Willebrand Factor (rvWF) is chromatographically purified by anion exchange chromatography on an anion exchanger of the quaternary amino type in a buffer solution comprising buffer substances and optionally salt.The buffer solutions are preferably free of stabilizers, amino acids and other additives. According to this method, highly pure recombinant vWF can be obtained, which is free from blood plasma proteins, especially free from Factor VIII, and is physiologically active.Further, the invention relates to a pharmaceutical preparation that contains rvWF, which is comprised of multimers with a high structural integrity.
    Type: Grant
    Filed: July 22, 1997
    Date of Patent: August 15, 2000
    Assignee: Immuno Aktiengesellschaft
    Inventors: Bernhard Fischer, Artur Mitterer, Friedrich Dorner, Hans-Peter Schwarz, Peter Turecek, Johann Eibl, Falko-Guenter Falkner, Uwe Schlokat, Wolfgang Mundt, Manfred Reiter, Renate Den-Bouwmeester
  • Recombinant cell clone having increased stability in serum- and protein-free medium and a method of recovering the stable cell clone and the production of recombinant proteins by using a stable cell clone
    Patent number: 6100061
    Abstract: Disclosed are a stable recombinant cell clone which is stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.
    Type: Grant
    Filed: June 19, 1998
    Date of Patent: August 8, 2000
    Assignee: Immuno Aktiengesellschaft
    Inventors: Manfred Reiter, Wolfgang Mundt, Friedrich Dorner